Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 5,000 Shares

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the completion of the transaction, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. The trade was a 12.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Glaukos Stock Performance

NYSE:GKOS opened at $109.33 on Friday. The company has a market capitalization of $6.28 billion, a P/E ratio of -70.99 and a beta of 0.69. The business has a fifty day simple moving average of $91.34 and a two-hundred day simple moving average of $92.70. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The firm’s quarterly revenue was up 38.1% compared to the same quarter last year. On average, analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Institutional Trading of Glaukos

Institutional investors and hedge funds have recently bought and sold shares of the company. UMB Bank n.a. grew its position in shares of Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 158 shares in the last quarter. Park Place Capital Corp raised its position in shares of Glaukos by 68.4% in the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares in the last quarter. REAP Financial Group LLC bought a new stake in Glaukos during the third quarter valued at $40,000. AlphaQuest LLC grew its position in Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 633 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. BTIG Research lifted their target price on shares of Glaukos from $104.00 to $116.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company raised their price objective on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Needham & Company LLC lifted their price objective on shares of Glaukos from $117.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday. Truist Financial set a $120.00 target price on shares of Glaukos in a report on Thursday, October 30th. Finally, Citigroup raised their price target on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $120.62.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.